Bioxytran Inc. announced a corporate update highlighting progress across its multi-platform pipeline. The company reiterated its focus on advancing ProLectin-M, its lead antiviral program, which is being developed under an active U.S. FDA Investigational New Drug $(IND)$ framework. In October 2025, Bioxytran completed a randomized, double-blind, placebo-controlled clinical trial for ProLectin-M, with trial data expected to inform Phase 3 design and regulatory submissions. Dose optimization work for ProLectin-M was completed in May 2025 to support further clinical planning and agency interactions. Bioxytran also reported continued development of its oxygen-transport platform, including a universal oxygen carrier (UOC) and the use of the FDA-approved MDX Viewer device for tissue oxygenation measurement. In July 2024, Bioxytran announced a joint venture with the Heme Foundation to develop the UOC as an alternative to blood transfusions. Additionally, in January 2025, the company released a cancer-focused preprint on galectin-3 modulation as a strategy to improve response to immune checkpoint inhibitors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1131467) on January 29, 2026, and is solely responsible for the information contained therein.